Ion channel pharmacology
DC Camerino, D Tricarico, JF Desaphy - Neurotherapeutics, 2007 - Springer
Because ion channels are involved in many cellular processes, drugs acting on ion
channels have long been used for the treatment of many diseases, especially those affecting …
channels have long been used for the treatment of many diseases, especially those affecting …
Taurine and skeletal muscle disorders
DC Camerino, D Tricarico, S Pierno, JF Desaphy… - Neurochemical …, 2004 - Springer
Taurine is abundantly present in skeletal muscle. We give evidence that this amino acid
exerts both short-term and long-term actions in the control of ion channel function and calcium …
exerts both short-term and long-term actions in the control of ion channel function and calcium …
Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal …
S Pierno, A De Luca, D Tricarico, A Roselli… - … of Pharmacology and …, 1995 - ASPET
To get insight into the potential risk of myopathy associated with therapy involving 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors, we evaluated in vivo and in vitro the …
coenzyme A reductase inhibitors, we evaluated in vivo and in vitro the …
[HTML][HTML] Therapeutic approaches to genetic ion channelopathies and perspectives in drug discovery
…, A Giustino, S Pierno, A De Luca, D Tricarico… - Frontiers in …, 2016 - frontiersin.org
In the human genome more than 400 genes encode ion channels, which are transmembrane
proteins mediating ion fluxes across membranes. Being expressed in all cell types, they …
proteins mediating ion fluxes across membranes. Being expressed in all cell types, they …
[HTML][HTML] Zoledronic acid modulation of TRPV1 channel currents in osteoblast cell line and native rat and mouse bone marrow-derived osteoblasts: cell proliferation …
…, R Latorre, MG Perrone, A Scilimati, D Tricarico - Cancers, 2019 - mdpi.com
Bisphosphonates (BPs) reduce bone pain and fractures by balancing the osteoblast/osteoclast
ratio. The behavior of ion channels in the presence of BPs is not known. To investigate …
ratio. The behavior of ion channels in the presence of BPs is not known. To investigate …
[HTML][HTML] Major channels involved in neuropsychiatric disorders and therapeutic perspectives
P Imbrici, DC Camerino, D Tricarico - Frontiers in genetics, 2013 - frontiersin.org
Voltage-gated ion channels are important mediators of physiological functions in the central
nervous system. The cyclic activation of these channels influences neurotransmitter release, …
nervous system. The cyclic activation of these channels influences neurotransmitter release, …
Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II.
M Cetrone, A Mele, D Tricarico - Current diabetes reviews, 2014 - ingentaconnect.com
The skeletal muscle atrophy and sarcopenia are negative prognostic factors in the treatment
of the diabetic aged-population. Insulin therapy stimulated protein anabolism in younger but …
of the diabetic aged-population. Insulin therapy stimulated protein anabolism in younger but …
[HTML][HTML] Impairment of skeletal muscle adenosine triphosphate–sensitive K+ channels in patients with hypokalemic periodic paralysis
D Tricarico, S Servidei, P Tonali… - The Journal of …, 1999 - Am Soc Clin Investig
The adenosine triphosphate (ATP)–sensitive K + (K ATP ) channel is the most abundant K +
channel active in the skeletal muscle fibers of humans and animals. In the present work, we …
channel active in the skeletal muscle fibers of humans and animals. In the present work, we …
Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+‐deficient rats
D Tricarico, M Barbieri, A Mele, G Carbonara… - The FASEB …, 2004 - Wiley Online Library
Carbonic‐anhydrase (CA) inhibitors are used in the treatment of hypokalaemic periodic
paralysis (hypoPP) and related channelopathies but their mechanism of action is unknown. …
paralysis (hypoPP) and related channelopathies but their mechanism of action is unknown. …
[HTML][HTML] Peripheral neuropathy under oncologic therapies: a literature review on pathogenetic mechanisms
…, C Calabrò, S Ferraiuolo, V Ungaro, D Tricarico… - International journal of …, 2021 - mdpi.com
Peripheral neurologic complications are frequent adverse events during oncologic
treatments and often lead to dose reduction, administration delays with time elongation of the …
treatments and often lead to dose reduction, administration delays with time elongation of the …